SNGX Stock Forecast: Soligenix, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 26 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Soligenix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (69): Sales and profits are climbing, and climbing faster than before.
Momentum (5): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SNGX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SNGX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 10 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 July 2025 | Alliance Global Partners | Maintains | Buy | $10 → $6.00 |
| 4 Dec 2020 | B. Riley FBR | Initiates | Buy | — |
| 4 Dec 2020 | B. Riley Securities | Initiates | Buy | $4.00 |
| 28 July 2020 | Dawson James | Downgrade | Neutral | $3.00 → $2.00 |
| 31 Jan 2018 | H.C. Wainwright | Downgrade | Neutral | — |
| 31 Jan 2018 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 14 Aug 2017 | Maxim Group | Maintains | Buy | $4.00 → $5.00 |
| 17 July 2017 | H.C. Wainwright | Initiates | Buy | — |
| 17 July 2017 | HC Wainwright & Co. | Initiates | Buy | — |
| 7 Sept 2016 | Aegis Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
SNGX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SNGX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Soligenix, Inc. returned −82.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SNGX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.9×
- EV / EBITDA
- —
Cheaper than 75% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −127.4%
- Return on assets
- −59.2%
- Dividend yield
- —
Higher than 11% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Soligenix, Inc. has a market value of $5.6M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$11.0M.
Free cash flow in the twelve months to 31 Mar 2026: −$10.8M.
Soligenix, Inc. employs 13 people.
Data provided by Twelve Data
SNGX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SNGX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Soligenix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SNGX
How does Ticker Nerd's model rank SNGX?
As at 21 Nov 2026, Soligenix, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (69 of 100).
What is the SNGX stock forecast for 2030?
No analyst covering Soligenix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.25 to $1.5 over the next 12 months.
How has SNGX stock performed over the past year?
Soligenix, Inc. returned -82.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Soligenix, Inc. do?
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases and other conditions with unmet medical needs. Its core business is organized into two segments: Specialized BioTherapeutics and Public Health Solutions.
About Soligenix, Inc.
Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases and other conditions with unmet medical needs. Its core business is organized into two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops treatments for orphan and inflammatory diseases, including cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease. The Public Health Solutions segment works on vaccines and therapeutics for biodefense and infectious disease threats, including ricin exposure, Ebola, Marburg, and other emerging viral infections. Soligenix Inc. plays a niche role in the healthcare market by targeting areas where treatment options remain limited, combining rare disease development with medical countermeasure research.
CEO Dr. Christopher J. Schaber Ph.D. · 13 employees · United States · https://www.soligenix.com